OTC · LFLY
Leafly Holdings, Inc.
$37.00$0.00 (0.0%)
Leafly Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.78% below the high.
Loading market information…
NASDAQ · GBS · USD
Stock price, earnings
Quote as of Oct 27, 2022, 04:00 AM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
GBS Inc.’s quoted price sits in the lower half of its reported 52-week range, 83.63% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow GBS Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Operating across North America and the Asia-Pacific region, GBS Inc. specializes in biosensor diagnostic technology. Its key product is the Saliva Glucose Biosensor, an innovative organic thin-film transistor designed for diabetes management that quantifies glucose levels directly from saliva. The company is also actively advancing a SARS-CoV-2 Biosensor, intended as a supplementary diagnostic tool to existing RNA virus detection tests, and is constructing a broad biosensor platform covering diagnostic modalities such as biochemistry, immunology, tumor markers, hormones, and nucleic acids. GBS Inc. maintains a research agreement with the Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic solutions. Founded in 2016 and headquartered in New York, New York, the company adopted its current name, GBS Inc., in September 2019, having previously operated as Glucose Biosensor Systems (Greater China) Holdings, Inc. It operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:31 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$37.00$0.00 (0.0%)
Leafly Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.78% below the high.
$2.07+$0.10 (+5.08%)
PAVmed Inc.’s quoted price sits in the lower half of its reported 52-week range, 92.72% below the high.
$0.86+$0.00 (+0.15%)
Phio Pharmaceuticals Corp.’s quoted price sits in the lower half of its reported 52-week range, 79.38% below the high.
$0.47$0.00 (0.0%)
ProSomnus, Inc.’s quoted price sits in the lower half of its reported 52-week range, 6.0% below the high.
$1.85+$0.23 (+14.2%)
BiomX Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.5% below the high.
$0.02+$0.00 (+27.39%)
BIOLASE, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.97% below the high.
$0.02$0.00 (0.0%)
Peak Bio, Inc.: Healthcare · Biotechnology.
$0.07-$0.10 (-60.05%)
TFF Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.41% below the high.
